Letter by Ma et al Regarding Article, “Neuroprotective Effects of the Glucagon-Like Peptide-1 Analog Exenatide After Out-of-Hospital Cardiac Arrest: A Randomized Controlled Trial”
This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
To the Editor:
We read with great interest the article by Wiberg et al1 that was recently published in Circulation. The authors conducted a randomized double-blind clinical trial to demonstrate the neuroprotective effect of the glucagon-like peptide-1 analog exenatide by acute administration of exenatide to comatose patients in the intensive care unit after out-of-hospital cardiac arrest. However, exenatide failed to reduce neuron-specific enolase levels and did not significantly improve a composite end point of death and neurological function in adults with out-of-hospital cardiac arrest.
The negative …